LONDON, Oct. 27, 2014 /PRNewswire/ -- This report analyzes the worldwide markets for Hemoglobin A1c Monitoring in US$ Million by the following Test Types: HbA1c Laboratory Testing, and HbA1c Point of Care Testing. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020.
Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 27 companies including many key and niche players such as -
Abbott Laboratories
ARKRAY, Inc.
Axis-Shield plc
Bayer Healthcare Diabetes Care
Beckman Coulter, Inc.
Download the full report: https://www.reportbuyer.com/product/197150/I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definition and Scope of Study I-3
HbA1c Laboratory Testing I-3
HbA1c Point of Care Testing I-3
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW II-1
A Quick Primer II-1
Growth Stimulants in a Nutshell II-2
Major Concerns II-2
Increasing Diabetes Prevalence - A Major Growth Propeller II-3
Table 1: Worldwide Prevalence of Diabetes Mellitus by Region
(2013 & 2035) (includes corresponding Graph/Chart) II-4
Table 2: Incidence of Diabetes in Select Countries (2013 &2035) (includes corresponding Graph/Chart) II-4
Table 3: World's Health Expenditure on Diabetes by Region
(2013E): Spending (in US$ Billion) by People Diagnosed with
Diabetes in the Age Group 20-79 Years to Treat Diabetes and
Manage Associated Complications (includes corresponding
Graph/Chart) II-5
Table 4: Global Expenditure on Diabetes Treatment (2012):Spending (in US$ Billion) by Income Strata (includescorresponding Graph/Chart) II-5Rapidly Aging Demographics and Growing Incidence of Diabetes:Major Driving Factors II-5Table 5: Elderly Population (60+ Years) as a Percentage ofTotal Population (2012 & 2050) (includes correspondingGraph/Chart) II-6
Table 6: Global Aging Population (60+) and their Proportion
of Total Population (2012) (includes corresponding
Graph/Chart) II-7
Increasing Obesity Levels Underpins Market Growth II-8
Table 7: Global Obesity Population (2013) (includes
corresponding Graph/Chart) II-8
Table 8: Prevalence of Adult Obesity in Select Countries(2012) (includes corresponding Graph/Chart) II-9Developing Nations: Future Growth Opportunities II-9Increase in Healthcare Spending in Emerging Markets II-10Table 9: Healthcare Spending as % of GDP in Select Countries(2011) (includes corresponding Graph/Chart) II-10Manufacturers Focus on Offering Products for Developing Markets II-11Near Patient Testing Gaining Ground II-11Regular HbA1c Test Keeps Heart Risk at Bay II-11Diabetes Diagnosis: Opportunities for HbA1c Testing II-11Is HbA1c Test Right in Being Recommended for DiagnosticPurposes? II-12Glycosylated Hemoglobin Tests: Paving Way for Early StageDiabetes Diagnosis II-12Technology Developments Revolutionize Diagnostics in DiabetesCare II-13POC Testing: Positive Opportunities in Store II-13Complex Competitive Environment Prevails in POC DiagnosticsMarket II-14POC HbA1c Tests: Significant Advantages over Lab Tests II-14Major Testing Methods in POC HbA1c Tests II-15Immunoassays II-15Boronate Affinity Chromatography II-15Micro-Optical Detection Methods II-16Select HbA1c POC Tests in the Market - A Comparison II-16Home Monitoring: Laced with Accuracy Concerns II-17Glycated Albumin - A Potential Threat to HbA1c? II-17Higher Levels of Glycosylated Hemoglobin Increases Risk of Death II-18Non-Invasive Glucose Meters and CBGM Devices Threatens HbA1cMarket II-18ESC and ADA Release Revised Guidelines for HbA1c Testing II-19Competitive Landscape II-20Table 10: Leading Players in the Global HbA1c Reagent Market(2012): Percentage Breakdown of Revenues for Bayer DiabetesCare, Siemens, and Others (includes correspondingGraph/Chart) II-20
2. DIABETES - A BRIEF PROFILE OF THE DISEASE II-21
What Causes Diabetes? II-21
Types of Diabetes II-21
Major Types of Diabetes II-22
Likely Complications II-22
Nephropathy (Kidney Disease) II-22
Diabetic Neuropathy (Nerve Damage) II-22
Retinopathy (Damage to the Eye and Blindness) II-23
Poor Healing of Infections and Wounds II-23
Impotence in Men II-23
Periodontal Disease II-23
Cardiovascular Disease II-23
Interpreting the A1c Range II-23
Blood Glucose Level Guidelines in the US II-24
A Glance at Key Diabetes Statistics II-24
Table 11: World Diabetes and Population Statistics (2013 &
2035) (includes corresponding Graph/Chart) II-24
Table 12: World Diabetes and Population Statistics (inMillion) by Region (2013E & 2035P) - Breakdown by Africa,Middle East and North Africa, Europe, North America andCaribbean Region, South and Central America, South East Asia,and Western Pacific (includes corresponding Graph/Chart) II-25Prevalence of Diabetes in Various Parts of the World II-26Table 13: Global Prevalence of Diabetes Mellitus (in Million)by Gender (2013E) - Breakdown by Region for Africa, MiddleEast and North Africa, Europe, North America and CaribbeanRegion, South and Central America, South East Asia, andWestern Pacific (includes corresponding Graph/Chart) II-26
Table 14: Global Prevalence of Diabetes Mellitus (in Million)
by Age Group (2013) - Breakdown by Region for Africa, Middle
East and North Africa, Europe, North America and Caribbean
Region, South and Central America, South East Asia, and
Western Pacific Region (includes corresponding Graph/Chart) II-27
Table 15: World Diabetes Market (2013 & 2035): Top 10 Regionswith Highest Number of People Diagnosed with Diabetes (inMillion) in Age Group 20-79 years (includes correspondingGraph/Chart) II-28
Table 16: Proportion of Undiagnosed Diabetes Cases (20-79
Years) by Region (2013E) (includes corresponding Graph/Chart) II-29
Table 17: Proportion of Deaths on Account of Diabetes inPeople Aged Less than 60 Years by Region (2013E) (includescorresponding Graph/Chart) II-29Therapeutic Options for Diabetes II-30Oral Medications for Type 2 Diabetes II-30Side Effects of Insulin Therapy II-31Maintaining A1c Test Result Below 7% II-31Common Diabetes Management Practices II-31
3. PRODUCT OVERVIEW II-32
Hemoglobin - A Brief II-32
Hemoglobin A1c- Description II-32
HbA1c Monitoring II-32
What is A1c? II-32
1. HbA1c Laboratory Testing II-33
2. HbA1c Point of Care Testing & Self-Monitoring II-33
Hemoglobin A1c (HbA1c) Test II-33
Interpreting HbA1c Test Readings II-34
Result of Hemoglobin A1c Test II-34
Clinical Use of A1c Testing II-34
Advantages of A1c Assessment & Interpretation II-35
Risks Associated with HbA1c Testing II-35
Methods of Measurement for Glycohemoglobin II-35
Why Opt for HbA1c Testing? II-36
The Diabetes Control & Complications Trial (DCCT) II-36
The Kumamoto and UK Prospective Studies II-36
Glycemia Tests Used in Monitoring Diabetes II-36
Urine Glucose Testing II-37
Glycated Protein Testing II-37
Table 18: Relation Between A1c Level and Mean Plasma
Glucose Levels II-37
HbA1c Test Types II-38
HbA1c Laboratory Testing II-38
Analytical Techniques Used for Quantifying HbA1c in Labs II-38
Standardization of HbA1c Results II-38
Table 19: CAP Accuracy Grading for HbA1c Measurements (
2007-2013) II-39
Select Laboratory-based HbA1c Testing Products/Analyzers II-39
HbA1c Point of Care Testing & Self-Monitoring II-42
Select Point of Care HbA1c Testing Products/ Analyzers II-43
Standardization of Glycated Hemoglobin Testing II-45
NGSP Standardization of HbA1c II-46
IFCC Standardization of HbA1c II-46
HbA1c Reporting II-46
A1c (%) and Corresponding eAG Number (in mg/dl or mmol/l) II-47
4. PRODUCT APPROVALS/INTRODUCTIONS II-48Piramal Enterprises Unveils Instant QDx Range of DiagnosticDevices II-48Roche Launches Cobas B 101 System for Managing Metabolic Syndrome II-48Convergys® Launches POC HbA1c Analyzer II-48Sanofi Showcases MyStar Extra® Self-Monitoring Meter II-49Roche Unveils New HbA1c Test for Diagnosis of Diabetes II-49Erba Mannheim Unveils New Hb-Vario HPLC System II-50EKF Launches Quo-Test POC HbA1c Analyzer II-50Roche Receives FDA Approval for COBAS INTEGRA 800 Tina-quantHbA1cDx Assay II-50Beckman Coulter Gets FDA Clearance for Hemoglobin A1c Assay Tests II-51Pointe Scientific Launches A1c Automated Assay for Beckman DXC600 Analyser II-51Dynacare Upgrades Hematology Software in Hemoglobin A1C Testing II-51Tosoh Bioscience Introduces GX Glycohemoglobin Analyzer II-51Siemens Secures CE Marking for DCA HbA1c Test Kit II-52EKF Obtains CE Mark for Quo-Lab POC HbA1c Analyser II-52Streck Launches A1c-Cellular Linearity Verification Material II-53Abbott Obtains CE Marking for ARCHITECT HbA1c (IA) FullyAutomated Assay II-53Tosoh Bioscience Develops ST AIA-PACK HbA1c Assay II-54Trinity Obtains FDA Approval for Premier Hb9210 HbA1c Device II-54Siemens Launches Fortified Version of DCA Vantage Analyzer II-55Tosoh Launches New Assay on its AIA-600II and AIA-360 Analyzers II-55
5. RECENT INDUSTRY ACTIVITY II-56
Quest Diagnostics Sells HemoCue Business to Radiometer II-56
Techne Takes Over Bionostics II-56
Express Diagnostics Takes Over Eveia Medical II-57
BioHermes Enters into Agreement to Acquire HbA1c Technology
from Scripps Laboratories II-57
HemoCue America Inks 5-Year Agreement with ARC II-57
Bio-Rad Laboratories Inks Development Agreement with Inpeco II-58
Danaher Acquires Beckman Coulter II-58
Alere Purchases Additional Shares of Axis-Shield II-58
EKF Diagnostics Inaugurates New Manufacturing Plant in the UK II-59
MinuteClinic Signs Agreement with Axis-Shield II-59
Trinity Inks Distribution Agreement with Menarini for Premier
Hb9210 II-59
6. FOCUS ON SELECT PLAYERS II-60Abbott Laboratories (US) II-60ARKRAY, Inc. (Japan) II-60Axis-Shield plc (UK) II-61Bayer Healthcare Diabetes Care (US) II-62Beckman Coulter, Inc. (US) II-62Bio-Rad Laboratories Inc (US) II-63Diazyme Laboratories Inc. (US) II-64EKF Diagnostics Holdings Plc (UK) II-64HEMOCUE® AB (Sweden) II-65Infopia Co. Ltd. (South Korea) II-65Menarini Diagnostics Ltd. (UK) II-65Roche Diagnostics (Switzerland) II-66Siemens Healthcare Diagnostics (Germany) II-66Tosoh Bioscience, Inc (US) II-67Trinity Biotech plc (Ireland) II-67
7. GLOBAL MARKET PERSPECTIVE II-68
Table 20: World Recent Past, Current & Future Analysis for
HbA1c Monitoring by Geographic Region - US, Canada, Japan,
Europe, Asia-Pacific (excluding Japan), Latin America and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2012 through 2020 (includes
corresponding Graph/Chart) II-68
Table 21: World Historic Review for HbA1c Monitoring byGeographic Region - US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World MarketsIndependently Analyzed with Annual Sales Figures in US$Million for Years 2006 through 2011 (includes correspondingGraph/Chart) II-69
Table 22: World 15-Year Perspective for HbA1c Monitoring by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),
Latin America and Rest of World Markets for Years 2006, 2014 &
2020 (includes corresponding Graph/Chart) II-70
Table 23: World Recent Past, Current & Future Analysis forLaboratory-based HbA1c Monitoring by Geographic Region - US,Canada, Japan, Europe, Asia-Pacific (excluding Japan), LatinAmerica and Rest of World Markets Independently Analyzed withAnnual Sales Figures in US$ Million for Years 2012 through2020 (includes corresponding Graph/Chart) II-71
Table 24: World Historic Review for Laboratory-based HbA1c
Monitoring by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2006 through 2011 (includes
corresponding Graph/Chart) II-72
Table 25: World 15-Year Perspective for Laboratory- basedHbA1c Monitoring by Geographic Region - Percentage Breakdownof Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific(excluding Japan), Latin America and Rest of World Markets forYears 2006, 2014 & 2020 (includes corresponding Graph/Chart) II-73
Table 26: World Recent Past, Current & Future Analysis for
Point-of-Care (POC)-based HbA1c Monitoring by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific (excluding
Japan), Latin America and Rest of World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2012 through 2020 (includes corresponding Graph/Chart) II-74
Table 27: World Historic Review for Point-of-Care (POC)-basedHbA1c Monitoring by Geographic Region - US, Canada, Japan,Europe, Asia-Pacific (excluding Japan), Latin America and Restof World Markets Independently Analyzed with Annual SalesFigures in US$ Million for Years 2006 through 2011 (includescorresponding Graph/Chart) II-75
Table 28: World 15-Year Perspective for Point-of-Care
(POC)-based HbA1c Monitoring by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe,
Asia-Pacific (excluding Japan), Latin America and Rest of
World Markets for Years 2006, 2014 & 2020 (includes
corresponding Graph/Chart) II-76
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
HbA1c - Increasingly Moving into Physician's Office III-1
HbA1c Testing for Diabetes Detection Gains Support III-1
ADA Recommends HbA1c Test for Diabetes Diagnosis III-1
ADA Recommends New Guidelines for HbA1c Testing for Certain
Patients III-2
Rising Inclination towards CLIA-Waived Tests III-2
Need for Further Stringency in Requirements Arises III-2
Healthcare Reform Legislation: Impact on Diabetes Diagnostics III-3
US Near Patient HbA1c Testing - A Highly Consolidated Market III-4
Table 29: Leading Players in the US Near Patient HbA1c
Testing Market (2013): Percentage Share Breakdown of
Revenues for Siemens, Axis-Shield, and Others (includes
corresponding Graph/Chart) III-4
Diabetes Statistics in North America and Caribbean Region III-5
Table 30: North American and Caribbean Regional Population
and Diabetes Prevalence Statistics (2013E) - Top Regions
with High Prevalence of Diabetes by Age Group and Gender
(includes corresponding Graph/Chart) III-5
Table 31: Diabetes and Population Statistics in NorthAmerica and Caribbean Region (2013 & 2035) (includescorresponding Graph/Chart) III-6Diabetes Statistics in the US - An Overview III-6Age Factor III-7Table 32: Number of Diabetics by Gender in the US (2013E)(in '000s) (includes corresponding Graph/Chart) III-7
Table 33: Number of Diabetics in the US by Age Group
(2013E) (in '000s) (includes corresponding Graph/Chart) III-7
Prevalence by Race/Ethnicity III-8
Table 34: US Market for Diabetes (2012): Percentage
Breakdown of Prevalence by Race/Ethnicity - Non-Hispanic
Blacks and Non-Hispanic Whites (includes corresponding
Graph/Chart) III-8
Mean HbA1c Scores at National Level III-9
Economic Burden of Diabetes in the US III-9
Table 35: Direct Medical Expenditure on Diabetes
Management in the US (2012): Percentage Share Breakdown of
Costs Incurred by Component (includes corresponding
Graph/Chart) III-9
Table 36: Indirect Costs of Diabetes in the US (2012):Percentage Share Breakdown by Component (includescorresponding Graph/Chart) III-10Product Approvals/Launches III-10Strategic Corporate Developments III-13Key Players III-15B.Market Analytics III-19Table 37: US Recent Past, Current & Future Analysis forHbA1c Monitoring by Segment - Laboratory Testing and Pointof Care Testing Markets Independently Analyzed with AnnualSales Figures in US$ Thousand for Years 2012 through 2020(includes corresponding Graph/Chart) III-19
Table 38: US Historic Review for HbA1c Monitoring by Segment-
Laboratory Testing and Point of Care Testing Markets
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2011(includes corresponding
Graph/Chart) III-20
Table 39: US 15-Year Perspective for HbA1c Monitoring bySegment - Percentage Breakdown of Dollar Sales forLaboratory Testing and Point of Care Testing Markets foryears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-21
2. CANADA III-22
A.Market Analysis III-22
Outlook III-22
Diabetes Statistics in Canada III-22
Table 40: Adult Diabetes Population by Gender in Canada
(2013) (In '000s) (includes corresponding Graph/Chart) III-22
Table 41: Adult Diabetes Population by Age Group in Canada(2013) (In '000s) (includes corresponding Graph/Chart) III-23B.Market Analytics III-23Table 42: Canadian Recent Past, Current & Future Analysisfor HbA1c Monitoring by Segment - Laboratory Testing andPoint of Care Testing Markets Independently Analyzed withAnnual Sales Figures in US$ Thousand for Years 2012 through2020 (includes corresponding Graph/Chart) III-23
Table 43: Canadian Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-24
Table 44: Canadian 15-Year Perspective for HbA1c Monitoringby Segment - Percentage Breakdown of Dollar Sales forLaboratory Testing and Point of Care Testing Markets foryears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-25
3. JAPAN III-26
A.Market Analysis III-26
Outlook III-26
ARKRAY, Inc. - A Major Player III-26
B.Market Analytics III-27
Table 45: Japanese Recent Past, Current & Future Analysis
for HbA1c Monitoring by Segment - Laboratory Testing and
Point of Care Testing Markets Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2012 through
2020 (includes corresponding Graph/Chart) III-27
Table 46: Japanese Historic Review for HbA1c Monitoring bySegment - Laboratory Testing and Point of Care TestingMarkets Independently Analyzed with Annual Sales Figures inUS$ Thousand for Years 2006 through 2011 (includescorresponding Graph/Chart) III-28
Table 47: Japanese 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-29
4. EUROPE III-30A.Market Analysis III-30Outlook III-30Positive Outlook for Diabetes Diagnostics Market in Europe III-30Proven Efficacy and Benefits of POCT HbA1C Tests Spur Adoption III-31Competitive Environment III-31Table 48: Leading Players in the European Point-of-CareHbA1c Tests Market (2011): Percentage Share Breakdown ofRevenues for Axis-Shield, Hemocue, Siemens HealthcareDiagnostics, and Others (includes correspondingGraph/Chart) III-32A Glance at Key Diabetes Statistics in Europe III-32Table 49: Diabetes and Population Statistics in Europe(2013 & 2035) (includes corresponding Graph/Chart) III-32
Table 50: European Population and Diabetes Prevalence
Statistics (2013E) - Select Regions with High Prevalence of
Diabetes for Age Groups (20-39, 40-59, and 60-79) and
Gender (includes corresponding Graph/Chart) III-33
B.Market Analytics III-34
Table 51: European Recent Past, Current & Future Analysis
for HbA1c Monitoring by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2012 through 2020 (includes corresponding
Graph/Chart) III-34
Table 52: European Historic Review for HbA1c Monitoring byGeographic Region - France, Germany, Italy, UK, Spain,Russia and Rest of Europe Markets Independently Analyzedwith Annual Sales Figures in US$ Thousand for Years 2006through 2011 (includes corresponding Graph/Chart) III-35
Table 53: European Recent Past, Current & Future Analysis
for HbA1c Monitoring by Segment - Laboratory Testing and
Point of Care Testing Markets Independently Analyzed with
Annual Sales Figures in US$ Thousand for Years 2012 through
2020 (includes corresponding Graph/Chart) III-36
Table 54: European Historic Review for HbA1c Monitoring bySegment - Laboratory Testing and Point of Care TestingMarkets Independently Analyzed with Annual Sales Figures inUS$ Thousand for Years 2006 through 2011 (includescorresponding Graph/Chart) III-37
Table 55: European 15-Year Perspective for HbA1c Monitoring
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-38
Table 56: European 15-Year Perspective for HbA1c Monitoringby Segment -Percentage Breakdown of Dollar Sales forLaboratory Testing and Point of Care Testing Markets foryears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-39
4a. FRANCE III-40
Market Analysis III-40
Table 57: French Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-40
Table 58: French Historic Review for HbA1c Monitoring bySegment - Laboratory Testing and Point of Care TestingMarkets Independently Analyzed with Annual Sales Figures inUS$ Thousand for Years 2006 through 2011 (includescorresponding Graph/Chart) III-41
Table 59: French 15-Year Perspective for HbA1c Monitoring by
Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-42
4b. GERMANY III-43A.Market Analysis III-43Outlook III-43Product Approvals/Introductions III-43Siemens Healthcare Diagnostics - A Key Player III-44B.Market Analytics III-45Table 60: German Recent Past, Current & Future Analysis forHbA1c Monitoring by Segment - Laboratory Testing and Pointof Care Testing Markets Independently Analyzed with AnnualSales Figures in US$ Thousand for Years 2012 through 2020(includes corresponding Graph/Chart) III-45
Table 61: German Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-46
Table 62: German 15-Year Perspective for HbA1c Monitoring bySegment - Percentage Breakdown of Dollar Sales forLaboratory Testing and Point of Care Testing Markets forYears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-47
4c. ITALY III-48
Market Analysis III-48
Table 63: Italian Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-48
Table 64: Italian Historic Review for HbA1c Monitoring bySegment - Laboratory Testing and Point of Care TestingMarkets Independently Analyzed with Annual Sales Figures inUS$ Thousand for Years 2006 through 2011 (includescorresponding Graph/Chart) III-49
Table 65: Italian 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-50
4d. THE UNITED KINGDOM III-51A.Market Analysis III-51Outlook III-51Diabetes Statistics & Management - An Insight III-51Rising Obesity Cases - Increased Risk of Diabetes III-51Type 1 Diabetes in Children III-52Table 66: Number of Type 1 Diabetics Per 100,000 Childrenin Select Countries (2011) (includes correspondingGraph/Chart) III-52NHS England Launches Action for Diabetes Plan III-52Strategic Corporate Developments III-53Key Players III-54B.Market Analytics III-56Table 67: UK Recent Past, Current & Future Analysis forHbA1c Monitoring by Segment - Laboratory Testing and Pointof Care Testing Markets Independently Analyzed with AnnualSales Figures in US$ Thousand for Years 2012 through 2020(includes corresponding Graph/Chart) III-56
Table 68: UK Historic Review for HbA1c Monitoring by Segment
- Laboratory Testing and Point of Care Testing Markets
Independently Analyzed with Annual Sales Figures in US$
Thousand for Years 2006 through 2011 (includes corresponding
Graph/Chart) III-57
Table 69: UK 15-Year Perspective for HbA1c Monitoring bySegment - Percentage Breakdown of Dollar Sales forLaboratory Testing and Point of Care Testing Markets forYears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-58
4e. SPAIN III-59
A.Market Analysis III-59
Outlook III-59
Product Launch III-59
B.Market Analytics III-60
Table 70: Spanish Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-60
Table 71: Spanish Historic Review for HbA1c Monitoring bySegment - Laboratory Testing and Point of Care TestingMarkets Independently Analyzed with Annual Sales Figures inUS$ Thousand for Years 2006 through 2011 (includescorresponding Graph/Chart) III-61
Table 72: Spanish 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-62
4f. RUSSIA III-63Market Analysis III-63Table 73: Russian Recent Past, Current & Future Analysis forHbA1c Monitoring by Segment - Laboratory Testing and Pointof Care Testing Markets Independently Analyzed with AnnualSales Figures in US$ Thousand for Years 2012 through 2020(includes corresponding Graph/Chart) III-64
Table 74: Russian Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-65
Table 75: Russian 15-Year Perspective for HbA1c Monitoringby Segment - Percentage Breakdown of Dollar Sales forLaboratory Testing and Point of Care Testing Markets forYears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-66
4g. REST OF EUROPE III-67
A.Market Analysis III-67
Outlook III-67
Strategic Corporate Developments III-67
Key Players III-69
B.Market Analytics III-71
Table 76: Rest of Europe Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-71
Table 77: Rest of Europe Historic Review for HbA1cMonitoring by Segment - Laboratory Testing and Point of CareTesting Markets Independently Analyzed with Annual SalesFigures in US$ Thousand for Years 2006 through 2011(includes corresponding Graph/Chart) III-72
Table 78: Rest of Europe 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-73
5. ASIA-PACIFIC III-74A.Market Analysis III-74Outlook III-74Diabetes Statistics - An Overview III-74Table 79: Diabetes and Population Statistics in WesternPacific (2013 & 2035) (includes corresponding Graph/Chart) III-75
Table 80: Western Pacific Population and Diabetes
Prevalence Statistics (2013E) - Select Regions with High
Prevalence of Diabetes for Various Age Groups (20-39,
40-59, and 60-79) and Gender (includes corresponding
Graph/Chart) III-76
Table 81: Diabetes and Population Statistics in South EastAsia (2013 & 2035) (includes corresponding Graph/Chart) III-77
Table 82: South East Asian Population and Diabetes
Prevalence Statistics (2013 Estimates) - Select Regions
with High Prevalence of Diabetes for Various Age Groups
(20-39, 40-59, and 60-79) and Gender (includes
corresponding Graph/Chart) III-77
B.Market Analytics III-78
Table 83: Asia-Pacific Recent Past, Current & Future
Analysis for HbA1c Monitoring by Geographic Region - China,
India and Rest of Asia-Pacific Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-78
Table 84: Asia-Pacific Historic Review for HbA1c Monitoringby Geographic Region - China, India and Rest of Asia-PacificMarkets Independently Analyzed with Annual Sales Figures inUS$ Thousand for Years 2006 through 2011 (includescorresponding Graph/Chart) III-79
Table 85: Asia-Pacific 15-Year Perspective for HbA1c
Monitoring by Geographic Region - Percentage Breakdown of
Dollar Sales for China, India and Rest of Asia-Pacific
Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) III-80
Table 86: Asia-Pacific Recent Past, Current & FutureAnalysis for HbA1c Monitoring by Segment - LaboratoryTesting and Point of Care Testing Markets IndependentlyAnalyzed with Annual Sales Figures in US$ Thousand for Years2012 through 2020 (includes corresponding Graph/Chart) III-81
Table 87: Asia-Pacific Historic Review for HbA1c Monitoring
by Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-82
Table 88: Asia-Pacific 15-Year Perspective for HbA1cMonitoring by Segment - Percentage Breakdown of Dollar Salesfor Laboratory Testing and Point of Care Testing Markets forYears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-83
5a. CHINA III-84
A.Market Analysis III-84
Outlook III-84
Increasing Diabetes Incidence Spurs Growth in Diabetes
Diagnostics Market III-84
Strategic Corporate Development III-85
B.Market Analytics III-86
Table 89: Chinese Recent Past, Current & Future Analysis for
HbA1c Monitoring by Segment - Laboratory Testing and Point
of Care Testing Markets Independently Analyzed with Annual
Sales Figures in US$ Thousand for Years 2012 through 2020
(includes corresponding Graph/Chart) III-86
Table 90: Chinese Historic Review for HbA1c Monitoring bySegment - Laboratory Testing and Point of Care TestingMarkets Independently Analyzed with Annual Sales Figures inUS$ Thousand for Years 2006 through 2011 (includescorresponding Graph/Chart) III-87
Table 91: Chinese 15-Year Perspective for HbA1c Monitoring
by Segment - Percentage Breakdown of Dollar Sales for
Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-88
5b. INDIA III-89A.Market Analysis III-89Outlook III-89HbA1c Testing on Growth Spree III-89Growth Stimulants & Challenges in a Nut Shell III-89Rising Diabetes Cases - Opportunities for HbA1c MonitoringMarket III-90Product Launch III-90B.Market Analytics III-91Table 92: Indian Recent Past, Current & Future Analysis forHbA1c Monitoring by Segment - Laboratory Testing and Pointof Care Testing Markets Independently Analyzed with AnnualSales Figures in US$ Thousand for Years 2012 through 2020(includes corresponding Graph/Chart) III-91
Table 93: Indian Historic Review for HbA1c Monitoring by
Segment - Laboratory Testing and Point of Care Testing
Markets Independently Analyzed with Annual Sales Figures in
US$ Thousand for Years 2006 through 2011 (includes
corresponding Graph/Chart) III-92
Table 94: Indian 15-Year Perspective for HbA1c Monitoring bySegment - Percentage Breakdown of Dollar Sales forLaboratory Testing and Point of Care Testing Markets forYears 2006, 2014 and 2020 (includes correspondingGraph/Chart) III-93
5c. REST OF ASIA-PACIFIC III-94
A.Market Analysis III-94
Outlook III-94
Diabetes Statistics in Australia III-94
Table 95: Diabetes Population Breakdown by Age Group in
Australia (2011-12) (includes corresponding Graph/Chart) III-94
Infopia Co. Ltd. (South Korea) - A Major Player III-95
B.Market Analytics III-95
Table 96: Rest of Asia-Pacific Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-95
Table 97: Rest of Asia-Pacific Historic Review for HbA1cMonitoring by Segment - Laboratory Testing and Point of CareTesting Markets Independently Analyzed with Annual SalesFigures in US$ Thousand for Years 2006 through 2011(includes corresponding Graph/Chart) III-96
Table 98: Rest of Asia-Pacific 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-97
6. LATIN AMERICA III-98A.Market Analysis III-98Outlook III-98Diabetes in Latin America - A Glance at Key Statistics III-98Table 99: Diabetes and Population Statistics in Central andSouth America (2013 & 2035) (includes correspondingGraph/Chart) III-99
Table 100: Central and South American Population and
Diabetes Prevalence Statistics (2013 Estimates) - Select
Regions with High Prevalence of Diabetes for Various Age
Groups (20-39, 40-59, and 60-79) and Gender (includes
corresponding Graph/Chart) III-99
B.Market Analytics III-100
Table 101: Latin American Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-100
Table 102: Latin American Historic Review for HbA1cMonitoring by Segment - Laboratory Testing and Point of CareTesting Markets Independently Analyzed with Annual SalesFigures in US$ Thousand for Years 2006 through 2011(includes corresponding Graph/Chart) III-101
Table 103: Latin American 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-102
7. REST OF WORLD III-103A.Market Analysis III-103Outlook III-103Diabetes Statistics in Africa and the Middle East III-103Table 104: African Diabetes and Population Statistics (2013 & 2035) (includes corresponding Graph/Chart) III-103
Table 105: African Population and Diabetes Prevalence
Statistics (2013) - Select Regions with High Prevalence of
Diabetes for Various Age Groups (20-39, 40-59, and 60-79)
and Gender (includes corresponding Graph/Chart) III-104
Table 106: Diabetes and Population Statistics in MiddleEast and North Africa (2013 & 2035) (includes correspondingGraph/Chart) III-105
Table 107: Middle East and North African Population and
Diabetes Prevalence Statistics (2013 Estimates) - Select
Regions with High Prevalence of Diabetes for Various Age
Groups (20-39, 40-59, and 60-79) and Gender (includes
corresponding Graph/Chart) III-106
B.Market Analytics III-107
Table 108: Rest of World Recent Past, Current & Future
Analysis for HbA1c Monitoring by Segment - Laboratory
Testing and Point of Care Testing Markets Independently
Analyzed with Annual Sales Figures in US$ Thousand for Years
2012 through 2020 (includes corresponding Graph/Chart) III-107
Table 109: Rest of World Historic Review for HbA1cMonitoring by Segment - Laboratory Testing and Point of CareTesting Markets Independently Analyzed with Annual SalesFigures in US$ Thousand for Years 2006 through 2011(includes corresponding Graph/Chart) III-108
Table 110: Rest of World 15-Year Perspective for HbA1c
Monitoring by Segment - Percentage Breakdown of Dollar Sales
for Laboratory Testing and Point of Care Testing Markets for
years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-109
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 27 (including Divisions/Subsidiaries - 35)
The United States (14)Canada (1)Japan (3)Europe (14)- Germany (3)- The United Kingdom (5)- Italy (1)- Rest of Europe (5)Asia-Pacific (Excluding Japan) (3)
Download the full report: https://www.reportbuyer.com/product/197150/
About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article